On November 6, 2026, Ro, the direct-to-patient telehealth company that started with erectile dysfunction prescriptions, announced Ro Research Lab. The unit will run AI over Ro's own real-world patient data to generate clinical findings. Ro says its vertically integrated platform combines clinical care, pharmacy, labs and patient-reported outcomes such as side effects, sleep, heart rate and weight "across millions of patient journeys." It wants to use that data to explain why patients respond so differently to the same treatment. "Why do some people lose 35% of their body weight on a medication while others lose 5%?" the release asks. Ro says early findings "will be labeled as such," and that results that hold up will go through peer review. Its list of topics includes "heart attacks, sex, food noise and mental health."

Why It Matters

**The men's-health telehealth platforms are becoming data businesses.** Ro's launch comes the same week as **Hims & Hers' Eli Lilly deal** ([our coverage](/stories/hims-eli-lilly-zepbound-foundayo-deal)) and a week after Ro debuted its **"Robin" AI health agent** ([our coverage](/stories/ro-robin-ai-health-agent)). The companies that built their customer bases on discreet ED and hair-loss prescriptions now want to profit from the longitudinal data those customers generate. Sexual health is explicitly on Ro's research list, and that data, including ED, PE and libido outcomes, is some of the most sensitive health information a consumer platform holds. That puts privacy at the centre of the story. Rival Hims & Hers is already being sued by the FTC, which alleges it shared sensitive health data with ad platforms ([our coverage](/stories/ftc-hims-hers-privacy-lawsuit)). Selling "insights" to pharma depends on how well data is de-identified, what patients consented to, and whether regulators treat derived analytics as a sale of health data under state laws like Washington's My Health My Data Act. Ro says findings will go through peer review. Whether it publishes its consent and de-identification terms alongside them will determine whether this is seen as research or as data brokerage. For investors, the move is a bet that real-world evidence becomes a revenue line as GLP-1 margins tighten.

The business model. The press release talks about discovery and sharing. Reuters (headlined "Ro launches healthcare research unit, plans to offer data to drugmakers") and the coverage that followed point to the commercial side: Ro plans to offer the data-driven insights to drugmakers. According to Analytics Insight, CEO Zach Reitano said the evidence could help insurers decide whether to cover expensive drugs and help pharma companies find the patients most likely to benefit. Ro is already working with Amgen on obesity-treatment access research. It has a separate research collaboration with Novo, and it sells cash-pay Zepbound, Wegovy and Lilly's oral Foundayo.

What it has published so far. Unite.AI reviewed the lab's early catalogue. It includes an abstract evaluating an in-house LLM that flags adverse-event messages from GLP-1 patients for care-team review. The authors report a 94% true-positive rate for detecting adverse-event content and a drop in median time to first clinical response from 115 minutes to 33 minutes across about 3,500 messages. That work dates to late 2024, so it predates the formal launch. The lab has also published an exercise-and-weight-loss analysis and a public GLP-1 pipeline tracker.

Sources

Update — 2026-11-08

Initial entry — story first created.